|
G |
Alb |
albumin |
affects binding |
ISO |
Amsacrine analog binds to ALB protein; Amsacrine binds to ALB protein |
CTD |
PMID:10803926 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Amsacrine binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression |
ISO |
Amsacrine results in decreased expression of ATG7 protein |
CTD |
PMID:37451322 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
ATM protein promotes the reaction [Amsacrine results in increased phosphorylation of H2AX protein] |
CTD |
PMID:37451322 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Amsacrine |
CTD |
PMID:16177561 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases response to substance |
ISO |
BCL2 protein results in decreased susceptibility to Amsacrine |
CTD |
PMID:10920913 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Amsacrine results in decreased expression of BCL2L1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA] |
CTD |
PMID:37451322 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
Amsacrine results in increased expression of BECN1 protein |
CTD |
PMID:37451322 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp2 |
caspase 2 |
increases splicing increases expression |
ISO |
Amsacrine results in increased splicing of CASP2 mRNA Amsacrine results in increased expression of CASP2 mRNA alternative form |
CTD |
PMID:14757846 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
Amsacrine results in increased degradation of and results in decreased expression of CCNA2 protein |
CTD |
PMID:11774253 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
Amsacrine results in increased degradation of and results in decreased expression of CCNB1 protein |
CTD |
PMID:11774253 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Amsacrine results in increased expression of CCNE1 protein |
CTD |
PMID:11774253 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Amsacrine |
CTD |
PMID:16969495 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
decreases expression multiple interactions |
ISO |
Amsacrine results in decreased expression of ELAVL1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; Amsacrine results in decreased expression of and results in decreased stability of ELAVL1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA]; GLX351322 inhibits the reaction [Amsacrine results in decreased expression of ELAVL1 protein] |
CTD |
PMID:37451322 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Amsacrine binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Amsacrine results in increased phosphorylation of H2AX protein ATM protein promotes the reaction [Amsacrine results in increased phosphorylation of H2AX protein] |
CTD |
PMID:37451322 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
Amsacrine binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:15148258 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Amsacrine results in increased expression of MAP1LC3B protein |
CTD |
PMID:37451322 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein] |
CTD |
PMID:37451322 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:37451322 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
increases activity multiple interactions affects response to substance |
ISO |
Amsacrine results in increased activity of MAPK12 protein [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine MAPK12 protein affects the susceptibility to Amsacrine |
CTD |
PMID:21878638 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Amsacrine results in decreased phosphorylation of MAPK3 protein [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:37451322 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases response to substance |
ISO |
MDM2 promoter SNP results in decreased susceptibility to Amsacrine |
CTD |
PMID:17575151 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mir22 |
microRNA 22 |
increases expression multiple interactions |
ISO |
Amsacrine results in increased expression of MIR22 [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein] |
CTD |
PMID:37451322 |
|
NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133
|
|
G |
Mir25 |
microRNA 25 |
decreases expression multiple interactions |
ISO |
Amsacrine results in decreased expression of MIR25 SIDT2 protein promotes the reaction [Amsacrine results in decreased expression of MIR25 protein] |
CTD |
PMID:37451322 |
|
NCBI chr12:17,042,932...17,043,015
Ensembl chr12:17,042,932...17,043,015
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Amsacrine results in decreased expression of MYC mRNA |
CTD |
PMID:11585056 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncl |
nucleolin |
affects response to substance |
ISO |
NCL protein affects the susceptibility to Amsacrine |
CTD |
PMID:16600179 |
|
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
ISO |
Amsacrine results in increased expression of NOX4 protein Amsacrine results in increased expression of and results in decreased degradation of NOX4 mRNA; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein] |
CTD |
PMID:37451322 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Amsacrine binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Amsacrine results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Rad51 |
RAD51 recombinase |
affects response to substance |
ISO |
RAD51 protein affects the susceptibility to Amsacrine |
CTD |
PMID:16600179 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
ISO |
Amsacrine results in increased expression of RARB mRNA alternative form |
CTD |
PMID:17608728 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Sidt2 |
SID1 transmembrane family, member 2 |
multiple interactions increases expression |
ISO |
SIDT2 protein promotes the reaction [Amsacrine results in decreased expression of MIR25 protein]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein] Amsacrine results in increased expression of SIDT2 protein |
CTD |
PMID:37451322 |
|
NCBI chr 8:46,232,379...46,248,913
Ensembl chr 8:46,232,383...46,248,700
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Amsacrine binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
Amsacrine results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:11459812 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Amsacrine results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:11459812 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions decreases response to substance affects response to substance |
ISO |
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Amsacrine; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine TOP2A gene mutant form results in decreased susceptibility to Amsacrine; TOP2A protein mutant form results in decreased susceptibility to Amsacrine TOP2A protein modified form affects the susceptibility to Amsacrine |
CTD |
PMID:1651812 PMID:10727526 PMID:11470519 PMID:11676865 PMID:12569090 PMID:16969495 PMID:21878638 More...
|
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Top2b |
DNA topoisomerase II beta |
decreases response to substance |
ISO |
TOP2B protein mutant form results in decreased susceptibility to Amsacrine |
CTD |
PMID:15322234 PMID:16239602 PMID:16549872 |
|
NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Tp53 |
tumor protein p53 |
increases activity increases expression multiple interactions increases glutathionylation |
ISO |
Amsacrine analog results in increased activity of TP53 protein Amsacrine results in increased expression of TP53 protein Amsacrine results in increased stability of and results in increased activity of TP53 protein Amsacrine results in increased glutathionylation of TP53 protein |
CTD |
PMID:11774253 PMID:12082016 PMID:16177561 PMID:17555331 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Amsacrine results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
ISO |
Amsacrine results in decreased expression of UBE2C mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Wrn |
WRN RecQ like helicase |
increases response to substance |
ISO |
WRN gene mutant form results in increased susceptibility to Amsacrine |
CTD |
PMID:10725663 |
|
NCBI chr16:58,763,517...58,898,604
Ensembl chr16:58,763,504...58,895,450
|
|